Oak Family Advisors LLC Sells 4,638 Shares of ResMed Inc. (NYSE:RMD)

Oak Family Advisors LLC cut its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 81.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,086 shares of the medical equipment provider's stock after selling 4,638 shares during the quarter. Oak Family Advisors LLC's holdings in ResMed were worth $248,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. True Wealth Design LLC lifted its position in shares of ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 110 shares during the period. Ashton Thomas Securities LLC acquired a new position in shares of ResMed during the third quarter valued at about $34,000. Rosenberg Matthew Hamilton bought a new position in shares of ResMed during the 4th quarter worth about $54,000. Capital Performance Advisors LLP acquired a new stake in shares of ResMed in the 3rd quarter valued at about $60,000. Finally, Venturi Wealth Management LLC increased its position in ResMed by 55.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 122 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RMD has been the subject of a number of research reports. JPMorgan Chase & Co. raised their price objective on ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. The Goldman Sachs Group initiated coverage on shares of ResMed in a report on Thursday, January 16th. They set a "buy" rating for the company. Finally, Royal Bank of Canada upped their target price on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $244.73.

ResMed Stock Performance

Shares of NYSE RMD traded down $5.47 during midday trading on Thursday, reaching $237.11. The company's stock had a trading volume of 992,644 shares, compared to its average volume of 1,030,356. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The stock has a market capitalization of $34.81 billion, a P/E ratio of 27.99, a PEG ratio of 1.69 and a beta of 0.70. The firm has a 50 day moving average price of $239.68 and a 200-day moving average price of $237.19. ResMed Inc. has a 12-month low of $170.56 and a 12-month high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, equities analysts predict that ResMed Inc. will post 9.41 earnings per share for the current year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be issued a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a yield of 0.89%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Insiders Place Their Bets

In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares in the company, valued at approximately $18,695,249.98. This represents a 2.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Witte Jan De sold 796 shares of the business's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the sale, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,094 shares of company stock valued at $2,704,941. Company insiders own 0.71% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.